Loading…
The Estée Lauder Companies
S&P 500
$35.2B
Market Cap
156.9
P/E
0.65
PEG
5.9%
ROCE
4.7%
ROE
2.43
D/E
11.0%
OPM
-17.0%
% from 52W High
67
α RS
🔍 EL is showing an earnings-catalyst setup because an ECS of 76.7 last quarter, RS Rating is 67, and it's within 17% of its 52-week high. Net: Broad signal stack, not a recommendation. ? ECS RS Rating 52W High
Sources
ECS 76.7 · RS Rating 67 · 17% from 52W high
⚖️ Compare 🔒 Generate Report 🔒 Research Packet 📚 Guides
🌏 Global Investor Returns
Currency-adjusted total returns for EL including FX impact
🌏
Click 🌏 Returns tab to load data
📈 Price History
Ratio Health
Excellent
Good
Average
Poor
By Category
📊 Sector Averages
About

The Estée Lauder Companies Inc. manufactures, markets, and sells skin care, makeup, fragrance, and hair care products worldwide. The company provides skin care products, including moisturizers, serums, cleansers, toners, eye care, body care, exfoliators, acne care and oil correctors, facial masks, and sun care products; and makeup products, such as foundations, powders, concealers and setting sprays, lipsticks, lip liners and lip glosses, mascaras, and eyeshadows and eyeliners, as well as compacts, brushes, and other makeup tools. It also offers fragrance products in various forms comprising parfum, eau de parfum, eau de toilette, eau de cologne, and body spray, as well as lotions, creams, powders, candles and soaps; and hair care products, including shampoos, conditioners, styling products, treatment, finishing sprays, and hair color products, as well as sells ancillary products and services. The company provides its products under the La Mer, Jo Malone London, TOM FORD, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, KILIAN PARIS, BALMAIN Beauty, Estée Lauder, Clinique, M·A·C, The Ordinary, Aveda, Bobbi Brown Cosmetics, Too Faced, Dr.Jart+, Bumble and bumble, Smashbox, Darphin Paris, Lab Series, Avestan, Loopha, Origins, NIOD, Aramis, and GLAMGLOW brands. It sells its products through department stores, duty-free retailers, specialty multi retailers, online pure players, upscale perfumeries and pharmacies, and top-tier salons and spas, as well as direct-to-consumer businesses across freestanding stores, and brand websites and third-party online platforms. The Estée Lauder Companies Inc. was founded in 1946 and is based in New York, New York.

Key Ratios Snapshot
📈 Growth Pattern
📊 Quick Scorecard
Loading…
⭐ Superinvestors Holding EL
View All Superinvestors →
Manager Shares Value % of Fund Period
Steve Cohen Point72 Asset Management 96.0K $6.9M 0.01% Mar 2026
Jim Simons Renaissance Technologies LLC 31.1K $2.2M 0.00% Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
🎙 Management Tone Confident Specific ↑ Improving 4 quarters Full tone analysis in Intelligence →
Good quarter Investor Presentation One-Pager? Q3 2026
Revenue
$3.712B
+5% YoY reported, +2% organic
Adjusted Operating Income
$557M
+38% YoY
Adjusted Operating Margin
15.0%
+360bps YoY
Adjusted Diluted EPS
$0.91
+40% YoY
What Went Right
  • Fragrance double-digit organic sales growth led by Le Labo, Tom Ford, Kilian.
  • Mainland China high single-digit growth, market share gains for fifth consecutive quarter.
  • Online organic sales grew 10% year-to-date, outperforming prestige beauty channel.
What to Watch
  • North America sales declined low single digits due to brick & mortar pressure and retailer bankruptcies.
  • Middle East conflict disruption expected to impact Q4 sales by ~2pp and EPS by $0.06.
  • Skincare innovation breadth lower vs prior year Q4; global geopolitical and tariff uncertainty.
Management Guidance
  • FY2026 organic net sales growth ~3% (high end of prior 2-3% range).
  • FY2026 adjusted operating margin 10.7%-11.0%; adjusted EPS $2.35-$2.45.
  • Preliminary FY2027: net sales growth 3%-5%, adjusted operating margin 12.5%-13.0%.
Investor Lens
The thesis is stronger after this call. Estée Lauder delivered a fifth consecutive quarter of organic sales growth and expanded operating margin by 360bps, demonstrating operational leverage from the PRGP and Beauty Reimagined. The raised full-year outlook and preliminary 2027 margin target of ~13% signal improving profitability, though investors will watch North America recovery and geopolitical risks in the Middle East.
From investor presentation · AI-generated analysis · Not investment advice
🔒
Premium Feature
Investor Presentation One-Pager — quarterly highlights, what went right/wrong & management guidance
Upgrade to Premium
Already a member? Log in
📈 STRONG Solid quarter with margin beat; FY27 outlook supports recovery.
Revenue
Revenue of $3.712B grew 5% reported and 2% organic, driven by double-digit fragrance growth and mid-single-digit growth in Mainland China. Online organic sales rose double-digit, and priority emerging markets grew double-digit. North America declined low single digits.
Profitability
Adjusted net earnings per share rose 40% to $0.91, with adjusted net income not explicitly stated but implied by EPS and share count. Operating income adjusted increased 38% to $557M.
Margins
Adjusted gross margin expanded 140bps to 76.4% driven by PRGP benefits and sales leverage, partly offset by tariffs and inflation. Adjusted operating margin expanded 360bps to 15.0% as non-consumer-facing expenses fell 4%.
Balance Sheet
Nine-month operating cash flow was $1.2B, up from $0.7B a year ago. CapEx of $306M was down 23% year-on-year. No debt or cash balance mentioned beyond $1.2B operating cash flow.
Key Risks
Geopolitical uncertainty and the Middle East conflict expected to weight on Q4 sales and EPS. Ongoing pressure in North American brick-and-mortar and retailer bankruptcies. Tariff and inflationary headwinds partially offset by cost savings.
Outlook
Fiscal 2026 organic sales growth now expected at ~3% (high end), operating margin 10.7%-11%, EPS $2.35-$2.45. Preliminary fiscal 2027 envisions 3%-5% organic sales growth and operating margin of 12.5%-13%.
Generated by AI · Q3 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter
🔍
🔎 See cross-company document search → ?
📞 Earnings Call Transcripts (5)
Q3 2026 Q3 2026 2026-05-01
Raised fiscal 2026 outlook with strong sales and margin expansion, led by China and emerging markets. Online and fragrance segments outperformed, while restructuring and cost efficiencies drove profitability. Fiscal 2027 guidance anticipates continued growth and margin improvement.
Q2 2026 Q2 2026 2026-02-05
Q2 delivered 4% organic sales growth, 43% EPS growth, and margin expansion, led by strong skincare, fragrance, and China performance. FY2026 outlook was raised, with top-end guidance targeted despite macro and travel retail headwinds.
Q1 2026 Q1 2026 2025-10-30
Delivered 3% organic sales growth and 300 bps operating margin expansion in Q1, led by strong performance in China, fragrance, and online channels. Reaffirmed full-year guidance, with ongoing cost discipline, innovation, and strategic investments driving confidence despite macro volatility.
Q4 2025 Q4 2025 2025-08-20
Fiscal 2025 saw an 8% organic sales decline, mainly from travel retail, but gross margin expanded and share gains were achieved in China, Japan, and the U.S. Fiscal 2026 guidance calls for flat to 3% organic sales growth, margin expansion, and continued cost savings, with risks from tariffs and market volatility.
Q3 2025 Q3 2025 2025-05-01
Organic net sales declined 9% year-over-year, with travel retail down 28% and non-travel retail down 3%, but gross margin expanded and EPS exceeded outlook. Market share gains in the U.S., China, and Japan were offset by ongoing macroeconomic and tariff risks.
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, ECS update, earnings-call, and SEC announcement for this company — in one chronological lane.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

Financial Model
Projections are built from each company's audited annual financials (Income Statement, Balance Sheet, Cash Flow) over the last 5 fiscal years. Forward assumptions — revenue growth %, EBITDA margin, D&A (USD millions), interest expense, tax rate, and capex — are AI-generated using historical context and refreshed twice a year: after the December results season and after the September/Q4 results season.

DCF Valuation
Fair Value = Σ(FCFt / (1+WACC)t) + Terminal Value. Terminal Value uses the Gordon Growth Model: FCF5 × (1+g) / (WACC−g). Default WACC: 10% (US risk-free ~4.5%, equity risk premium ~5.5%). Default terminal growth: 3% (long-run US nominal GDP proxy).

CAGR Tracker
Expected 5-year CAGR = (DCF Fair Value / Current Price)1/5 − 1. Assumes fair value is reached in exactly 5 years — a mechanical estimate only.

Data Sources & Limitations
Financial statements sourced from public filings. Prices updated daily. Forward assumptions are AI-generated. All monetary values in USD millions. Non-US ADR companies may have currency conversion inaccuracies. Models are point-in-time and do not update intra-quarter or account for M&A, macro shocks, or extraordinary items.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.